Literature DB >> 31080734

Mycobacterium abscessus Periprosthetic joint infection following bilateral Total Knee arthroplasty.

Rajesh Malhotra1, Kiran Bala2, Deepak Gautam1, Aakashneel Bhattacharya2, Ashit Bhusan Xess2, Pooja Pandey2, Santosh Verma2, Urvashi B Singh2.   

Abstract

Periprosthetic joint infection (PJI) can be protracted, incapacitating, needing multiple interventions and could even lead to mortality. Early post-operative PJI has been ascribed to peri-operative introduction of highly virulent bacteria, while delayed post-operative to low-virulence bacteria. Non-tuberculous mycobacteria (NTM) do not figure in the usual list of etiological agents. We report a case of difficult diagnosis of bilateral PJI caused by Mycobacterium abscessus, following bilateral total knee arthroplasty in an elderly male, but treated successfully despite prolonged infection. M. abscessus complex comprises a group of rapidly growing, multidrug-resistant NTM, capable of forming biofilms on prostheses, responsible for wide spectrum of hospital acquired infections. M. abscessus as a cause of PJI is not reported widely. There are a few cases described in literature worldwide. There are no policy guidelines available for treating such cases. High clinical suspicion, with a concerted effort to grow and identify the causal pathogen is important. Standard anti-tubercular therapy is not recommended for treatment due to inherent resistance. Complete excision of infected tissues and removal of prosthesis along with prolonged combination antimicrobial regimen is the treatment of choice.

Entities:  

Keywords:  Mycobacterium abscessus; Periprosthetic joint infection; Total knee replacement

Year:  2019        PMID: 31080734      PMCID: PMC6505037          DOI: 10.1016/j.idcr.2019.e00542

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Introduction

Prosthetic joint infections (PJI) are one of the most challenging complications of joint replacement surgery [1]. Most early onset post-operative cases are ascribed to virulent bacteria such as Staphylococcus aureus, while late-onset cases are ascribed to low virulence bacteria. Of late, NTM are being reported from several device related infections but PJI due to non-tubercular mycobacteria (NTM) are relatively under-reported [[2], [3], [4], [5], [6], [7]]. NTM, especially Mycobacterium abscessus, are capable of forming bio-films on prosthetic material and hence are difficult to treat using antibacterials alone. Removal of prosthetic material with prolonged antimicrobial combination regimen is the treatment of choice. The present case describes delay in diagnosis and arduous but successful management of bilateral PJI after total knee replacement (TKR) caused by Mycobacterium abscessus.

Case report

A 78-year-old diabetic and hypertensive male patient, presented with pain, swelling and discharging sinuses in both knees, 5 weeks after sequential bilateral TKR at a peripheral hospital, with no response to cloxacillin and ofloxacin. Discharge revealed acid-fast bacilli (AFB), but was negative for cartridge-based-nucleic-acid-amplification test (Xpert MTB/Rif). Empirical anti-tubercular therapy (ATT) was initiated, (rifampin, isoniazid, pyrazinamide and ethambutol) with minimal response, stopped after seven months, followed by bilateral knee debridement and poly-exchange but the discharge continued. Eleven months after index surgery, he underwent implant removal and articulating antimicrobial cement spacer application in both knees (Fig. 1a) and was referred to our institute. He presented with difficulty in mobilization due to displaced cement spacer in both knees, thick purulent discharge from left knee and copious sero-purulent discharge from right knee. Laboratory investigations revealed Erythrocyte Sedimentation Rate (ESR) of 22 mm and a C-reactive protein (CRP) at 27 mg/L. All antibacterials were stopped, tissue samples excised from sinus edge and discharge from both knees sent for microbiological analysis.
Fig. 1

a: Radiograph of both knees in Antero-Posterior view showing cement spacer in situ. b: Clinical photograph showing Ilizarov ring fixator in right knee and clean, healed skin on left side following thorough debridement on both sides. c: Radiograph showing arthrodesed right knee and revision knee prosthesis in the left knee.

a: Radiograph of both knees in Antero-Posterior view showing cement spacer in situ. b: Clinical photograph showing Ilizarov ring fixator in right knee and clean, healed skin on left side following thorough debridement on both sides. c: Radiograph showing arthrodesed right knee and revision knee prosthesis in the left knee. Bacteriology and mycology laboratory reports were inconclusive. In the mycobacteriology laboratory, the Ziehl Neelsen stain and Gene-Xpert MTB/RIF from the material was negative. Some growth was observed on MacConkey agar on day 3. Colonies were confirmed as AFB and grew on Lowenstein Jensen’s media with 5% NaCl. Nitrate reduction test was negative. MGIT automated liquid culture system (Becton Dickinson, NJ, USA) revealed the growth of the same phenotype. As per the growth pattern and biochemical properties the isolate was identified as Mycobacterium abscessus. The isolate was sequenced for 16S ribosomal gene and confirmed as M. abscessus, The sequence was submitted to Genbank and granted Accession No. MH720215. Drug susceptibility test was done by broth micro-dilution assay as per CLSI guidelines [8]. The isolate was sensitive to amikacin, clarithromycin, linezolid and rifampin but resistant to imipenem. The patient was started on rifabutin 300 mg, clarithromycin 1000 mg and injection amikacin 500 mg daily. Baseline audiometry, renal function tests, ECG and liver function tests were within normal limits. Serial QTc monitoring, renal function, electrolytes and liver enzymes were closely monitored. After 3 weeks of antibacterial, thorough debridement of right knee with sinus excision, and distal femoral canal curettage followed by arthrodesis using Ilizarov ring fixator was done. After two weeks, the left knee was debrided and left with antimicrobial impregnated cement spacer in-situ. After another 8 weeks of antibacterials, the left knee was re-implanted with revision knee prosthesis and the patient was mobilized with full weight bearing on both knees. The intraoperative tissue samples on both knees revealed negative culture for mycobacteria. Post-intervention, there was no fresh discharge from both knee joints (Fig. 1b). PET scan at end of four months revealed no metabolic uptake. Amikacin was replaced with oral levofloxacin due to bilateral sensory-neural hearing loss for higher frequencies after 6 months. By end of 7 months, his wounds were clean and dry, ESR, CRP were within normal limits. Ilizarov ring fixator was removed and knee brace used as the X-ray showed signs of trabeculae across the distal femur and proximal tibia. Currently the patient is on one-and-half year follow-up and is antimicrobial free for last four months. He is mobile without braces, is able to bear weight on both his legs for last two months, and a normal for age renal and liver functions. His latest X-rays showed bony ankylosis of right knee with stable revision knee arthroplasty implants in situ in his left knee (Fig. 1c).

Discussion

Rapidly growing mycobacteria (RGM) are ubiquitous in environment and reported worldwide. They are implicated in nosocomial infections following medical or surgical interventions leading to wound infections and sepsis. M. fortuitum, M. chelonae and M. abscessus are potentially pathogenic RGM responsible for 90% of the clinical cases [2,9]. M. abscessus complex demonstrates inducible macrolide resistance due to a novel erm gene (erm41) [10]. Mycobacterium abscessus is resistant to disinfectants and therefore can cause post-surgical and post-procedural infections. It is associated with a wide range of skin and subcutaneous tissue, respiratory tract, central nervous system, pulmonary and ocular infections, bacteremia and disseminated infections [[11], [12], [13], [14], [15], [16]]. Possible sources for nosocomial outbreaks include contaminated saline, disinfectants or surgical equipments and contact transmission between patients [14]. Incidence of PJI ranges from 2.05% to 2.18% after total knee replacement (TKR) with primary arthroplasties [17]. There are 43 cases of PJI reported by RGM, including 17 cases of knee-PJI caused by RGM, including Mycobacterium chelonae, M. smegmatis, M. fortuitum, M. wolinskyi and M. abscessus [1,2,10]. M. abscessus is reported in eight cases, one from India [2,3,[5], [6], [7],9]. (Table 1). Diagnosis is frequently delayed due to lack of clinical suspicion or lack of appropriate laboratory support.
Table 1

Summary of all the cases of prosthetic knee joint infections due to Mycobacterium abscessus reported in the literature.

S.noAuthor’s ReferenceAge/sexUnderlying DiseaseRegionArthroplasty & period of prosthetic Joint InfectionOrganism CulturedAntibiotic RegimenSurgical InterventionFinal Outcome
1Eid AJ et al.71/FRheumatoid arthritisNot knownKnee (652 days)M. abscessusCFX & CLR (2 weeks)Resection arthroplastyPalliative care (3 weeks)
2Ryu SW et al.58/FDegenerative joint disease2001, KoreaLeft Knee arthroplasty (21 days)M. abscessusKanamycin+Clarithromycin+ Pyrazinamide(9months)DebridementPalliative care (not known)
Amk (2 mnts Perioperatively)
3Wang SX et al72 /FIntra articular steroid injection& osteoarthritis2011, TaiwanRight Knee arthroplasty (5 months)M. abscessus & M. fortuitumDoxycycline+Ciprofloxacin+ Clarithromycin(5 months)Reimplantation at 4 monthsNo relapse (43 weeks)
Amk (2 mnts Perioperatively)
4Amit P et al71/FDegenerative joint disease2010, New Delhi, IndiaRight Knee arthroplasty (2 years)M. abscessusCLR+LEV+AMK(3 WEEKS)Resection arthroplastyNo Relapse
CLR+LEV+IMP(6 WEEKS)Debridement at 4.5 monthsFollow up 104 weeks
CLR+LEV (13 WEEKS)Reimplantation at 6.5 months
6Kim et al83/FDegenerative joint disease2017, South KoreaRight Knee arthroplasty (18 Days)M. abscessusCefoxitin (IV)Clarithromycin+ Amikacin (IV)Moxifloxacin (6months)Resection arthroplastyNo Relapse
Debridement at 7 monthsFollow up 4 years and 3months
Reinfection after 10 months of surgery(Open debridement and polyethylene insert exchange)
71/FDegenerative joint disease2017, South KoreaRight Knee arthroplasty (13 month)M. abscessusATT (6weeks)Cefoxitin (IV)open debridement, open debridement with removal of prosthesesand insertion of antibiotic cement spacers, Revision TKA, open debridement (7Months)No relapse
Clarithromycin+Amikacin (IV)Follow up 2 years
(Cefoxitin replaced by tigecycline) (6mnts+10 months)Reimplantation (15 months after revision TKA)
7Spanyer et al61/FKnee arthritis2018, Boston, USALeft Knee arthroplasty (9 days)M. abscessus(IV) cefoxitin, oral clarithromycin, and thrice-weekly intravenous amikacin. (15 weeks)Resection arthroplastyNo relapse
Debridement at 4.5 monthsFollow up 4 years
Reimplantation at 3.5 months
8Present Case78/MDegenerative Joint diseaseNew Delhi, India 2018Bilateral Total Knee arthroplastyM. abscessusRifabutin + Clarithromycin+ Amikacin (IV)Debridement at 4 monthsNo relapse
Prosthesis removal and antibiotic spacer insertion 11 monthsFollow up 1 year
Arthrodesis of the right knee
Reimplantation left knee after 2 months
Summary of all the cases of prosthetic knee joint infections due to Mycobacterium abscessus reported in the literature. This case reported discharge from surgical wounds, without fever since the TKR. Mycobacterial infection was suspected considering his prolonged illness and repeated negative bacterial cultures. Clear temporal association of symptoms with surgery and involvement of both knees, with a typical presentation suggestive of RGM, suggests that infection was likely acquired from the hospital setting during or after initial intervention. RGM infections are resistant to several groups of antibacterials and combination therapy of oral macrolides with parenteral medications (amikacin, cefoxitin or imipenem) is advocated for serious bone and soft tissue infections by M. abscessus. Isolate in this case was resistant to imipenem and there is limited availability of cefoxitin in India. Rifabutin is active against M. abscessus and inhibits clarithromycin resistant strains [18], hence regimen was designed with rifabutin, clarithromycin and intravenous amikacin. There are no guidelines for the optimal empiric therapy or duration for PJI caused by RGMs. PJI due to Mycobacterium abscessus have been infrequently reported and no specific guidelines exist to inform treatment. M. abscessus is resistant to disinfectants, intrinsically resistant to first line ATT and increasingly reported resistant to macrolides; are known to form biofilms on prosthetic material and hence difficult to eradicate. High clinical suspicion, accurate laboratory diagnosis, combination of surgical and carefully designed medical regimen can eradicate non-responding PJI even after delayed diagnosis and a long course of infection.

Conflict of interest

None.

Research funding

None.

Consent

Written informed consent has been taken from the patient regarding publication of the case report and is available for review as per the request of Editor-in-chief.
  3 in total

1.  T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren.

Authors:  Binayak Rimal; Hunter R Batchelder; Elizabeth Story-Roller; Chandra M Panthi; Chavis Tabor; Eric L Nuermberger; Craig A Townsend; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2022-05-31       Impact factor: 5.938

2.  Sulfonamides complexed with metals as mycobacterial biofilms inhibitors.

Authors:  Pauline Cordenonsi Bonez; Vanessa Albertina Agertt; Grazielle Guidolin Rossi; Fallon Dos Santos Siqueira; Josiéli Demétrio Siqueira; Lenice Lorenço Marques; Gelson Noe Manzoni de Oliveira; Roberto Christ Vianna Santos; Marli Matiko Anraku de Campos
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-01-17

3.  Nontuberculous mycobacterial infection of the knee after arthrocentesis for idiopathic hemarthrosis: A case report.

Authors:  Akihiro Moritake; Shigeshi Mori; Masato Kamiya; Kenji Yamazaki; Shingo Aoyama; Masao Akagi; Daisuke Togawa
Journal:  Ann Med Surg (Lond)       Date:  2021-04-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.